Trial Profile
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Veliparib (Primary) ; Ferumoxytol
- Indications Solid tumours
- Focus Adverse reactions
- 04 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 04 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 02 Jul 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.